Stacy W Gray

List of Publications by Year
in descending order

95 papers	4,355 citations	117625 34 h-index	114465 63 g-index
99 all docs	99 docs citations	99 times ranked	7622 citing authors

#	Article	IF	Citations
1	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	30.7	508
2	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	6.2	342
3	Physicians' Attitudes About Multiplex Tumor Genomic Testing. Journal of Clinical Oncology, 2014, 32, 1317-1323.	1.6	203
4	Cancer Information Scanning and Seeking in the General Population. Journal of Health Communication, 2010, 15, 734-753.	2.4	168
5	Differences in information seeking among breast, prostate, and colorectal cancer patients: Results from a population-based survey. Patient Education and Counseling, 2010, 81, S54-S62.	2.2	155
6	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine, 2016, 8, 79.	8.2	151
7	Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas. Journal of Thoracic Oncology, 2013, 8, 322-328.	1.1	145
8	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	6.2	137
9	Antiâ€“PD-1 Inhibitorâ€“Related Pneumonitis in Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	3.4	135
10	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
11	Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1593.	7.4	110
12	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	2.4	108
13	Internet use leads cancer patients to be active health care consumers. Patient Education and Counseling, 2010, 81, S63-S69.	2.2	105
14	Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing. Journal of Oncology Practice, 2012, 8, 329-335.	2.5	104
15	Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 2013, 15, 860-867.	2.4	99
16	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	1.6	96
17	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories: Table 1.. Journal of the National Cancer Institute, 2016, 108, djv351.	6.3	86
18	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	1.6	79

#	Article	IF	Citations
19	CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1231-1242.	4.4	73
20	Seeking Cancer-Related Information From Media and Family/Friends Increases Fruit and Vegetable Consumption Among Cancer Patients. Health Communication, 2012, 27, 380-388.	3.1	63
21	Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precision Oncology, 2018, 2, 1-13.	3.0	63
22	A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine, 2013, 15, 824-832.	2.4	62
23	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	2.4	60
24	Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. Genetics in Medicine, 2019, 21, 2781-2790.	2.4	55
25	Tumor Board Participation Among Physicians Caring for Patients With Lung or Colorectal Cancer. Journal of Oncology Practice, 2015, 11, e267-e278.	2.5	54
26	Looking Beyond the Internet: Examining Socioeconomic Inequalities in Cancer Information Seeking Among Cancer Patients. Health Communication, 2012, 27, 806-817.	3.1	51
27	Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware. Journal of Clinical Oncology, 2003, 21, 3191-3193.	1.6	48
28	Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry. Journal of the National Cancer Institute, 2018, 110, 1059-1066.	6.3	48
29	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 2017, 19, 787-795.	2.4	46
30	Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Research and Treatment, 1998, 52, 147-158.	2.5	45
31	Class, race, ethnicity and information needs in post-treatment cancer patients. Patient Education and Counseling, 2011, 85, 432-439.	2.2	45
32	Examining Cross-Source Engagement With Cancer-Related Information and Its Impact on Doctorâ€“Patient Relations. Health Communication, 2009, 24, 723-734.	3.1	43
33	Class, race and ethnicity and information avoidance among cancer survivors. British Journal of Cancer, 2013, 108, 1949-1956.	6.4	43
34	The effects of genomic germline variant reclassification on clinical cancer care. Oncotarget, 2019, 10, 417-423.	1.8	40
35	How Do Cancer Patients Navigate the Public Information Environment? Understanding Patterns and Motivations for Movement Among Information Sources. Journal of Cancer Education, 2010, 25, 360-370.	1.3	39
36	Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. Journal of Clinical Oncology, 2017, 35, 636-644.	1.6	34

#	Article	IF	Citations
37	Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer. Cancer, 2012, 118, 1404-1411.	4.1	33
38	Risk Information Exposure and Direct-to-Consumer Genetic Testing for BRCA Mutations among Women with a Personal or Family History of Breast or Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1303-1311.	2.5	31
39	Attitudes Toward Research Participation and Investigator Conflicts of Interest Among Advanced Cancer Patients Participating in Early Phase Clinical Trials. Journal of Clinical Oncology, 2007, 25, 3488-3494.	1.6	29
40	Oncologists' Experiences With Drug Shortages. Journal of Oncology Practice, 2015, 11, e154-e162.	2.5	27
41	Colon cancer patient information seeking and the adoption of targeted therapy for onâ€label and offâ€label indications. Cancer, 2009, 115, 1424-1434.	4.1	23
42	Patientâ€“Clinician Information Engagement Improves Adherence to Colorectal Cancer Surveillance after Curative Treatment: Results from a Longitudinal Study. Oncologist, 2012, 17, 1155-1162.	3.7	23
43	Consumer Perspectives on Access to Directâ€toâ€Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience. Milbank Quarterly, 2017, 95, 291-318.	4.4	22
44	Association of Physician Peer Influence With Subsequent Physician Adoption and Use of Bevacizumab. JAMA Network Open, 2020, 3, e1918586.	5.9	22
45	Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. JCO Precision Oncology, 2020, 4, 620-631.	3.0	22
46	Oncologistsâ€™ perspectives on post-cancer treatment communication and care coordination with primary care physicians. European Journal of Cancer Care, 2017, 26, e12628.	1.5	20
47	Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. Annals of Surgical Oncology, 2016, 23, 990-997.	1.5	17
48	Medical Oncologistsâ€™ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. Journal of Oncology Practice, 2017, 13, e185-e196.	2.5	17
49	Marketing of Personalized Cancer Care on the Web: An Analysis of Internet Websites. Journal of the National Cancer Institute, 2015, 107, .	6.3	16
50	Accessibility and Quality of Online Cancer-Related Clinical Trial Information for NaÃ¯ve Searchers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1629-1631.	2.5	15
51	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	1.5	15
52	Variations in Surgeon Treatment Recommendations for Lobectomy in Early-Stage Non-Small-Cell Lung Cancer by Patient Age and Comorbidity. Annals of Surgical Oncology, 2010, 17, 1581-1588.	1.5	14
53	How does patientâ€clinician information engagement influence selfâ€reported cancerâ€related problems?. Cancer, 2011, 117, 2569-2576.	4.1	14
54	The impact of risk information exposure on women's beliefs about directâ€toâ€consumer genetic testing for BRCA mutations. Clinical Genetics, 2012, 81, 29-37.	2.0	14

#	Article	IF	Citations
55	Interactive or static reports to guide clinical interpretation of cancer genomics. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 458-464.	4.4	14
56	Germline mutations and age at onset of lung adenocarcinoma. Cancer, 2021, 127, 2801-2806.	4.1	14
57	Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 866-872.	4.9	14
58	Update on Direct-to-Consumer Marketing in Oncology. Journal of Oncology Practice, 2012, 8, 124-127.	2.5	13
59	A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. JAMA Health Forum, 2022, 3, e220603.	2.2	13
60	An Analysis of the Association Between Cancer-Related Information Seeking and Adherence to Breast Cancer Surveillance Procedures. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 167-174.	2.5	12
61	Factors influencing cancer genetic somatic mutation test ordering by cancer physician. Journal of Translational Medicine, 2020, 18, 431.	4.4	11
62	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. JCO Precision Oncology, 2020, 4, 307-318.	3.0	10
63	Associations between Cancer-Related Information Seeking and Receiving PET Imaging for Routine Cancer Surveillanceâ€"An Analysis of Longitudinal Survey Data. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 481-489.	2.5	9
64	Factors contributing to disparities in mortality among patients with nonâ€"smallâ€cell lung cancer. Cancer Medicine, 2018, 7, 5832-5842.	2.8	9
65	Quality in the Age of Precision Medicine: The Clinician Perspective. Journal of Oncology Practice, 2016, 12, 839-843.	2.5	8
66	Recall of Genomic Testing Results Among Patients with Cancer. Oncologist, 2021, 26, e2302-e2305.	3.7	8
67	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer, 2018, 124, 2205-2211.	4.1	6
68	Influence of Peer Physicians on Intensity of End-of-Life Care for Cancer Decedents. Medical Care, 2019, 57, 468-474.	2.4	6
69	A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers. Clinical Lung Cancer, 2021, , .	2.6	6
70	Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?. Journal of Personalized Medicine, 2021, 11, 741.	2.5	5
71	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clinical Lung Cancer, 2021, 22, e703-e707.	2.6	5
72	Oncologistsâ€™ perceptions of the usefulness of cancer survivorship care plan components. Supportive Care in Cancer, 2021, 29, 945-954.	2.2	4

#	Article	IF	Citations
73	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice, 2021, 17, e1821-e1829.	2.9	4
74	Tip of the Tongue. New England Journal of Medicine, 2016, 375, 880-886.	27.0	3
75	ReCAP: Oncologistsâ€™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	2.5	3
76	Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. JCO Oncology Practice, 2021, 17, e999-e1011.	2.9	3
77	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. Journal of Clinical Oncology, 2017, 35, 1514-1514.	1.6	3
78	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.. Journal of Clinical Oncology, 2016, 34, 1500-1500.	1.6	2
79	What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. Journal of Oncology Practice, 2018, 14, 139-140.	2.5	1
80	Cancer patientsâ€™ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study.. Journal of Clinical Oncology, 2014, 32, 1535-1535.	1.6	1
81	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	1.6	1
82	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. Journal of Clinical Oncology, 2019, 37, 6531-6531.	1.6	1
83	Direct-to-consumer genetic testing and its potential impact on patient care: what oncologists need to know. Community Oncology, 2011, 8, 419-422.	0.2	0
84	Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics.. , 2013, , .		0
85	Pediatric oncology provider views on biopsying solid tumors in children with relapsed or refractory disease for the purpose of genomic profiling.. Journal of Clinical Oncology, 2016, 34, 10566-10566.	1.6	0
86	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine.. Journal of Clinical Oncology, 2016, 34, 11565-11565.	1.6	0
87	What does the general population think about chemotherapy shortages?. Journal of Clinical Oncology, 2017, 35, 6530-6530.	1.6	0
88	Optimizing somatic genomic reporting and physician interpretation with web-based, interactive technologies.. Journal of Clinical Oncology, 2017, 35, 1517-1517.	1.6	0
89	Abstract 4273: Variant reclassifications in hereditary cancer genetics and their implications for clinical care. , 2017, , .		0
90	Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.. Journal of Clinical Oncology, 2018, 36, 6529-6529.	1.6	0

#	Article	IF	Citations
91	Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer. , 2018, , .		0
92	Differences in comprehension of somatic genomic profiling between younger and older adults with advanced genitourinary cancer.. Journal of Clinical Oncology, 2018, 36, 228-228.	1.6	0
93	Hypertension and use of bevacizumab among patients treated in community settings.. Journal of Clinical Oncology, 2019, 37, e18279-e18279.	1.6	0
94	Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.. Journal of Clinical Oncology, 2019, 37, 1518-1518.	1.6	0
95	Crossâ€sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. Journal of Genetic Counseling, 0, , .	1.6	0